新達控股(08471.HK)5月13日完成配售5000萬股
格隆匯5月13日丨新達控股(08471.HK)宣佈,配售事項已於2020年5月13日落實完成,合共5000萬股配售股份已按配售價每股配售股份0.113港元成功配售予九名獨立承配人。
預期配售事項所得款項總額及所得款項淨額(經扣除配售費用及配售事項產生之其他相關開支)分別為565萬港元及約541萬港元。預期約541萬港元(相當於配售事項所得款項淨額全部金額)將用作廣州半城雲的營運資金,其與集團於信息科技業發展相關。廣州半成雲的主要業務為向中國中小型企業提供線上及線下電子商業解決方案(又稱軟體即服務(SaaS))以及提供雲端商業及營銷解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.